

CURRICULUM VITAE



Saiedeh Razi-Soofiyan

Tabriz University of Medical sciences

Sina Educational, Research and Treatment Center, Clinical Research Development Unit,
Azadi Ave., Tabriz, Iran.

Tel: 041 354198473 (office)

Email: saeedeh,razi@gmail.com

PERSONAL INFORMATION

Date/Place of birth: 25 Dec 1985, Tabriz

Nationality: Iranian

Marital status: Married

EDUCATIONAL BACKGROUND

2007- 2009 B.Sc of Medical Laboratory Science, Tabriz University of Medical sciences

2010- 2013 M.Sc of Immunology, Tabriz University of Medical sciences

2013-2018 Ph.D of Molecular Medicine, Tabriz University of Medical sciences

EDUCATIONAL INFORMATION

1. MSc graduation score (18.65 out of 20)
2. MSc Thesis score (19.10 out of 20)
3. MSC Thesis title: Investigating the simultaneous effect of gene therapy with IL-12 and GM-CSF on tumor mass regression in the mouse model
4. Ph. D graduation score (17.50 out of 20)
5. Ph. D Thesis score (19.7 out of 20)
6. Ph. D Thesis title: investigating the combination therapy with CIP2A- siRNA and docetaxel on human prostate cancer cell line

CURRENT STATUS

1. Research advisor in Clinical Research Development Unit of Sina Educational, Research and Treatment Center, Tabriz University of Medical sciences, Tabriz, Iran

2. Expert in charge of Clinical Research Development Unit of Sina Educational, Research and Treatment Center, Tabriz University of Medical sciences, Tabriz, Iran

Publications

• Books

- Writing the "Everything about interferons" in Persian, Yavarian Publications, ISBN: 978-622-6836-66-1. Ardabil-Iran, 2020.

• Published scientific papers from 2013 up to 2023

1. Soofiyani SR, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. *Advanced pharmaceutical bulletin*. 2013;3(2):249.
2. Soofiyani SR, Hallaj-Nezhadi S, Lotfipour F, Hosseini AM, Baradaran B. Gene therapy based on interleukin-12 loaded chitosan nanoparticles in a mouse model of fibrosarcoma. *Iranian journal of basic medical sciences*. 2016;19(11):1238.
3. Razi Soofiyani S, Kazemi T, Lotfipour F, Mohammad hosseini A, Shanehbandi D, Hallaj-Nezhadi S, et al. Gene therapy with IL-12 induced enhanced anti-tumor activity in fibrosarcoma mouse model. *Artificial cells, nanomedicine, and biotechnology*. 2016;44(8):1988-93.
4. Soofiyani SR, Hejazi MS, Baradaran B. The role of CIP2A in cancer: a review and update. *Biomedicine & Pharmacotherapy*. 2017;96:626-33.
5. Soofiyani SR, Hoseini AM, Mohammadi A, Shahgoli VK, Baradaran B, Hejazi MS. siRNA-mediated silencing of CIP2A enhances docetaxel activity against PC-3 prostate cancer cells. *Advanced Pharmaceutical Bulletin*. 2017;7(4):637.
6. RaziSoofiyani S, Kazemi T, Lotfipour F, Mohammadnejad L, Hallaj-Nezhadi S, Shotorbani SS, et al. The effects of gene therapy with granulocyte-macrophage colony-stimulating factor in the regression of tumor masses in fibrosarcoma mouse model. *Journal of Cancer Research and Therapeutics*. 2017;13(2):362-6.
7. Soofiyani SR, Lotfipour F, Kazemi T, Hoseini AM, Shanehbandi D, Mohammadnejad L, et al. Combined interleukin 12 and granulocyte-macrophage colony-stimulating factor gene therapy synergistically suppresses tumor growth in the murine fibrosarcoma. *International Journal of Cancer Management*. 2017;10(10).
8. Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S, Abediazar S, Shoja MM, Ardalan M, et al. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. *Reviews in medical virology*. 2021;31(3):e2176.

9. Hejazian SM, Khatibi SMH, Barzegari A, Pavon-Djavid G, Soofiyan SR, Hassannejhad S, et al. Nrf-2 as a therapeutic target in acute kidney injury. *Life sciences*. 2021;264:118581.
10. Pahlavan Y, Nasr MM, Abdolahinia ED, Pirdel Z, Soofiyan SR, Siahpoush S, et al. Prominent roles of microRNA-142 in cancer. *Pathology-Research and Practice*. 2020;216(11):153220.
11. Abdkarimi S, Razi Soofiyan S, Elham G, Mashhadi Abdolahi H, Safarzadeh E, Baradaran B. Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. *European Journal of Cancer Care*. 2020;29(5):e13268.
12. Asgharian P, Tazekand AP, Soofiyan SR, Hosseini K, Martorell M, Tarhriz V, et al. Quercetin impact in pancreatic cancer: an overview on its therapeutic effects. *Oxidative Medicine and Cellular Longevity*. 2021;2021.
13. Soofiyan SR, Hosseini K, Forouhandeh H, Ghasemnejad T, Tarhriz V, Asgharian P, et al. Quercetin as a novel therapeutic approach for lymphoma. *Oxidative Medicine and Cellular Longevity*. 2021;2021.
14. Ebrahimzadeh S, Ahangari H, Soleimanian A, Hosseini K, Ebrahimi V, Ghasemnejad T, et al. Colorectal cancer treatment using bacteria: focus on molecular mechanisms. *BMC microbiology*. 2021;21(1):1-12.
15. Ahangari H, Yazdani P, Ebrahimi V, Soofiyan SR, Azargun R, Tarhriz V, et al. An Updated review on production of food derived bioactive peptides; focus on the psychrotrophic bacterial proteases. *Biocatalysis and Agricultural Biotechnology*. 2021;35:102051.
16. Soofiyan SR, Ahangari H, Soleimanian A, Babaei G, Ghasemnejad T, Safavi SE, et al. The role of circadian genes in the pathogenesis of colorectal cancer. *Gene*. 2021;804:145894.
17. Soofiyan SR, Hosseini K, Soleimanian A, Abkhouei L, Hoseini AM, Tarhriz V, et al. An overview on the role of mir-451 in lung cancer: diagnosis, therapy, and prognosis. *MicroRNA*. 2021;10(3):181-90.
18. Kazemi E, Soofiyan SR, Ahangari H, Eyvazi S, Hejazi MS, Tarhriz V. Chemolithotroph bacteria: from biology to application in medical sciences. *Crescent Journal of Medical and Biological Sciences*. 2021;8(2).
19. Baradaran B, Mohammadi A, Shamekhi S, Majidazar N, Dilmaghani A, Soofiyan SR, et al. A novel method for the development of plasmid DNA-loaded nanoliposomes for cancer gene therapy. *Drug Delivery and Translational Research*. 2021:1-13.
20. Asgharian P, Tazekand AP, Hosseini K, Forouhandeh H, Ghasemnejad T, Ranjbar M, et al. Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets. *Cancer cell international*. 2022;22(1):257.
21. Soofiyan SR, Hosseini K, Ebrahimi T, Forouhandeh H, Sadeghi M, Beirami SM, et al. Prognostic value and biological role of miR-126 in breast cancer. *MicroRNA*. 2022;11(2):95-103.
22. Hosseini K, Soofiyan SR, Zamiri RE, Farjami A, Dilmaghani A, Mahdavi M, et al. Layered double hydroxide nanostructures as drug-carriers in treatment of breast cancer. *Nanomedicine Journal*. 2022;9(2).

23. Asgharian P, Quispe C, Herrera-Bravo J, Sabernavaei M, Hosseini K, Forouhandeh H, et al. Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update. *Frontiers in Pharmacology*. 2022;13.
24. Talebi M, Ebrahimi V, Rasouli A, Farjami A, Soofiyan SR, Soleimani A, et al. A new insight on feasibility of pre-, pro-, and synbiotics-based therapies in Alzheimer's disease. *Journal of Reports in Pharmaceutical Sciences*. 2022;11(2):141.
25. Farjami A, Montazersaheb S, Soofiyan SR, Akbarzadehlaleh P, Salatin S. Biopharmaceuticals for prevention of COVID-19: A scoping review. *Asian Pacific Journal of Tropical Medicine*. 2022;15(6):245.
26. Nakhband A, Farahzadi R, Saeedi N, Barzegar H, Montazersaheb S, Soofiyan SR. Correlation of stress and depression with cancer initiation and progression; a mechanistic review. *Current Drug Targets*. 2022.
27. Arabzadeh A, Faghfuri E, Soofiyan SR, Abdolahinia ED, Siapush S, Nejati K, et al. Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review. *Advanced Pharmaceutical Bulletin*. 2022.

PRESENTATIONS

1. The effect of gene therapy with GM-CSF in the regression of tumor masses in mouse model. 6th International Congress of Laboratory & Clinic. Iran.2014.
2. The effect of IL-12 gene therapy CSF in the regression of tumor masses in mouse model. 12th International Congress of Immunology & Allergy. Iran. 2014.
3. Down-regulated expression of Toll-like receptor 2 and4 mRNA in peripheral blood monocyte from patients with vitiligo. 12th International Congress of Immunology & Allergy. Iran. 2014.
4. Down-regulated expression of Myd-88 in peripheral blood monocyte from patients with vitiligo. 12th International Congress of Immunology & Allergy. Iran. 2014.
5. Investigating the simulatous effect of gene therapy with IL-12 and GM-CSF in the regression of tumor masses in mouse model. 1st National student congress of cancer. Iran. 2014.
6. CIP2A: A novel therapeutic target in cancer therapy. 2nd National Conference of Molecular Medicine AND Treatment of Diseases. Iran. 2016.
7. Comparison of cancerous inhibitor of protein phosphatase 2A gene expression in prostate cancer cell lines. 13th International Congress of Immunology & Allergy. Iran. 2016.
8. Silencing of cancerous inhibitor of PP2A inhibits proliferation and promotes apoptosis in human prostate cancer. 1st West Asia Cancer Conference. Iran. 2016.
9. Gene therapy based on IL-12 loaded chitosan nano-particles in a mouse model of fibrosarcoma. 3rd National Congress of Molecular Medicine. Iran. 2016
10. Silencing of CIP2A enhances the anti-tumor activity of doctaxel against PC-3 prostate cancer cells. 3rd International Nastaran symposium. Iran. 2017.

11. Comparison of two agitation methods: Circular and Flatbed movement in the production of platelet product. 12th International Congress of Laboratory & Clinic. Iran. 2019.

ADMINISTRATIVE EXPERIENCE

- Member of Executive committee of 13th international congress of Immunology and Allergy Tabriz, Iran, 2016
- Reviewer of 3rd International Nastaran symposium. 2017
- Reviewing experience in ABP journal, cancer control journal, Pharmaceutical Sciences journal, Biotechnology Letters journal, Medical Science Monitor, International Journal of Peptide Research and Therapeutics.

Memberships

- Iranian Society for Immunology and Allergy
- Iranian Society for Molecular Medicine
- Student Research Committee of Tabriz University of Medical Sciences, from 2013 to 2017.
- Iranian smart and talented students' office in Tabriz University of Medical Sciences from 2010 to 2017.

Teaching EXPERIENCE

- Teaching Molecular diagnosis methods of disease for Ph.D. students of Molecular Medicine.
- Teaching Molecular bases of diseases for Ph.D. students of Molecular Medicine.
- Teaching practical immunology for B.Sc. students of nursing and midwifery.

RESEARCH EXPERIENCE

- Experience in tissue culture, cellular proliferation and apoptosis assays, MTT assay, Electrophoresis techniques, ELISA (enzyme-linked immunosorbant assay), q-RT-PCR, Conventional PCR, Western blotting, fluorometry, immunocytochemistry, Gene silencing, Transfection, Transformation, Bacteria culture, Wound-healing assay, Matrigel assay and Laboratory animals manipulation

Language Skills

- Azari; Mother tongue
- Persian; Official language
- English; Good

طرح های تحقیقاتی

- بررسی تاثیر همزمان ژن درمانی با Il-12 و GM-CSF در پسرقت توده های توموری در مدل موشی
- بررسی درمان ترکیبی docetaxel و CIP2A siRNA در رده سلولی سرطان پروستات انسانی
- بررسی حساسیت آنتی بیوتیک های جدید داپتوماپسین، لینزولید، کینوپریستین و دالفوپریستین علیه استافیلوکوکوس اورئوس مقاوم به متی سیلین جمع آوری شده از بخش های مراقبت ویژه بزرگسالان بیمارستان سینا، تبریز
- سنتز ترمودینامیکی کامپوزیت انسولین-کیتوزان-کتیرا مقاوم در برابر اسید جهت تحویل خوراکی انسولین
- بررسی کیفیت آموزش سرپایی در مراکز آموزشی پژوهشی و درمانی دانشگاه علوم پزشکی تبریز از دیدگاه فراگیران
- طراحی و اجرای پرسشنامه بررسی دیدگاه کادر درمان، بیمار و همراهان بیمار در خصوص محدودیت افراد ملاقات کننده
- بررسی اثرات ضدسرطانی کوئرسیتین بر روی رده سلول سرطانی لنفوما در شرایط in vitro و تاثیر آن در میزان بیان میکرو آر آن های مهم بویژه miR-451
- بررسی تاثیر هموپرفیوژن بر میزان بقا و پیامدهای بالینی در بیماران مبتلا به کووید ۱۹
- بررسی اثر حفاظتی گاما اوریزانول بر آسیب ایسکمی- باز رسانی کلیه در مدل حیوانی رت
- بررسی اثرات FTY720 روی بیوژنز میتوکندریایی سلولهای توبولار کلیه تحت استرس اکسیداتیو
- تاثیر آنتی اکسیدانت اداراون بر بیان سیرتوئین ها در مدل اینویترو آسیب حاد کلیه (AKI)
- ارزیابی تاثیر فینگولیمود روی موش های صحرایی آسیب دیده از ایسکمی- ریپرفیوژن کلیوی
- بررسی شکایت های شنوایی در بیماران کرونایی بستری شده

افتخارات علمی:

- دانشجوی پژوهشگر برجسته وزارت بهداشت، درمان و آموزش پزشکی، دریافت لوح تقدیر از معاونت تحقیقات و فناوری وزارت بهداشت دکتر ملک زاده، سال ۱۳۹۶
- عضو اصلی دفتر استعدادهای درخشان استعدادهای دانشگاه علوم پزشکی تبریز در دوره های کارشناسی ارشد و Ph.D

سوابق خدمت تخصصی در دانشگاه علوم پزشکی تبریز:

- عضو شورای پژوهشی مرکز آموزشی، پژوهشی و درمانی سینا

- کارشناس آزمایشگاه مرکز تحقیقات پزشکی مولکولی
- کارشناس آزمایشگاه مرکز آموزشی، پژوهشی و درمانی سینا